Quick Listen: Scrip’s Five Must-Know Things
In this week's podcast version of Five Must-Know Things, hear about new results for Lilly in Alzheimer’s, a US delay for AbbVie, progress for Zolgensma in the UK, challenges for AstraZeneca’s coronavirus vaccine, and a Scrip roundtable on industry lessons from the pandemic.
Join us for an audio catch-up on the major events in the biopharma industry in the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.
This episode covers insights for the business week ended 19 March 2021, including: new results for Lilly in Alzheimer’s; a US delay for AbbVie; progress for Zolgensma in the UK; challenges for AstraZeneca’s coronavirus vaccine; and a Scrip roundtable on lessons from the pandemic.
These and all other podcasts are available on the Informa Pharma Intelligence channel on Apple Podcasts, Google Podcasts, SoundCloud and TuneIn - and also now on Spotify Podcasts - and via smart speakers if one of these platforms has been set up as your default podcast provider.
Stories mentioned in this episode:
(Also see "Lilly’s New Anti-Amyloid Play Hinges On Tau Bet" - Scrip, 15 Mar, 2021.)
(Also see "AbbVie’s Rinvoq Delay By US FDA Could Foreshadow More Trouble For JAKs" - Scrip, 17 Mar, 2021.)
(Also see "Novartis Steers Zolgensma Towards Commercial Success In Europe" - Scrip, 12 Mar, 2021.)
(Also see "AstraZeneca’s COVID-19 Vaccine PR Nightmare Won’t Faze Investors" - Scrip, 16 Mar, 2021.)
(Also see "Pandemic Perspectives: R&D Lessons Learned From The COVID Year" - Scrip, 17 Mar, 2021.)